LEGN
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Legend Biotech receives U.S. FDA clearance of its IND application for LB2501, an investigational in vivo CAR-T therapy targeting CD19 and CD20Oct 15, 2026
- Legend Biotech launches the inaugural ELITE Grant Program to advance next-generation CAR-T innovation in multiple myelomaOct 1, 2026
- Legend Biotech presents CARVYKTI data showing half of patients with relapsed/refractory multiple myeloma remained alive and progression-free five years after a single infusionSep 25, 2026
- Legend Biotech established clinical proof-of-concept for LB2501 in relapsed or refractory B-cell non-Hodgkin lymphomaJun 15, 2026
- Legend Biotech presents groundbreaking 5-year survival data for CARVYKTI® in multiple myeloma at ASCO 2025Jun 4, 2025